{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T01:01:21Z","timestamp":1700010081076},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen). Thirteen months later, a pelvic recurrence was diagnosed, and the patient received nine cycles of FOLFOX-6 plus bevacizumab, resulting in a clinical complete response but the development of pancytopenia. Bone marrow biopsy was consistent with therapy-related acute myelogenous leukemia. Chromosome analysis showed structural rearrangements with partial deletions of the long arms of chromosomes 5, 7, 20, and 21, as well as trisomy of chromosome 8 and losses of chromosomes 3 and 11. Induction chemotherapy led to remission, but the patient died two months later from complications of colon cancer progression. It is likely that the leukemia was related to the oxaliplatin administration.<\/jats:p>","DOI":"10.1634\/theoncologist.11-3-261","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T22:02:49Z","timestamp":1142892169000},"page":"261-262","source":"Crossref","is-referenced-by-count":13,"title":["Oxaliplatin-Related Acute Myelogenous Leukemia"],"prefix":"10.1093","volume":"11","author":[{"given":"Benedito A.","family":"Carneiro","sequence":"first","affiliation":[{"name":"a Department of Medicine, Kellogg Cancer Care Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Kaminer","sequence":"additional","affiliation":[{"name":"a Department of Medicine, Kellogg Cancer Care Center"},{"name":"c Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Eldibany","sequence":"additional","affiliation":[{"name":"b Department of Pathology and Laboratory Medicine, Evanston Northwestern Healthcare, Evanston, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrika","family":"Sreekantaiah","sequence":"additional","affiliation":[{"name":"d Dianon Systems (Labcorp), Stratford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Kaul","sequence":"additional","affiliation":[{"name":"b Department of Pathology and Laboratory Medicine, Evanston Northwestern Healthcare, Evanston, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gershon Y.","family":"Locker","sequence":"additional","affiliation":[{"name":"a Department of Medicine, Kellogg Cancer Care Center"},{"name":"c Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,3,1]]},"reference":[{"key":"2021122208160831800_R1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10245330410001701503","article-title":"Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment","volume":"9","author":"Rund","year":"2004","journal-title":"Hematology"},{"key":"2021122208160831800_R2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMe048336","article-title":"Insights into leukemogenesis from therapy-related leukemia","volume":"352","author":"Pedersen-Bjergaard","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122208160831800_R3","article-title":"Secondary acute promyelocytic leukemia following irinotecan and oxaliplatin for advanced colon cancer","volume-title":"Ann. Oncol","author":"Merrouche","year":"2005"},{"key":"2021122208160831800_R4","first-page":"369","article-title":"Mutagenic activity of topoisomerase I inhibitors","volume":"1","author":"Hashimoto","year":"1995","journal-title":"Clin Cancer Res"},{"key":"2021122208160831800_R5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s101470300009","article-title":"Therapy-related erythroleukemia caused by the administration of UFT and mitomycin C in a patient with colon cancer","volume":"8","author":"Nakamori","year":"2003","journal-title":"Int J Clin Oncol"},{"key":"2021122208160831800_R6","first-page":"144","article-title":"Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors","volume":"71","author":"Takeyama","year":"2000","journal-title":"Int J Hematol"},{"key":"2021122208160831800_R7","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.11-3-261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.11-3-261","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/3\/261\/41850857\/oncolo_11_3_261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/11\/3\/261\/41850857\/oncolo_11_3_261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T13:20:40Z","timestamp":1640179240000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/11\/3\/261\/6395767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":7,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,3,1]]},"published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.11-3-261","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,3,1]]},"published":{"date-parts":[[2006,3,1]]}}}